EORTC presentations at ESMO 2014 Congress

EORTC investigators will present the results of their cancer research at ESMO 2014 Congress, 26-30 September 2014 in Madrid.

Joint Symposium: ESMO-ASCO: The Evolution of the clinical trial landscape

Monday, September 29, 11:00 AM – 12:30 PM, Room: Granada

Abstract 121IN

Denis Lacombe portraitDenis Lacombe

Can Collaborative Molecular Screening Platforms support new forms of cancer clinical research? The example of the EORTC SPECTA program.

Proffered Paper session: Melanoma and other skin tumors

Saturday, September 27, 2:00 PM – 3:45 PM, Room: Barcelona

Abstract 10870

Alexander-EggermontEggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Karra Gurunath R, de Pril V, Suciu S, Testori A

Efficacy, safety, and quality of life data from the EORTC 18071 phase III trial of ipilimumab versus placebo after complete resection of stage III melanoma

Proffered Paper session: Sarcoma

Monday, September 29, 3:45 PM – 5:30 PM, Room: Sevilla

Abstract 14150

WTA-van-der-Graaf-portraitW.T.A. van der Graaf, A. Le Cesne, O. Mir, H. Gelderblom, A. Italiano, S. Marreaud, I. Judson, S. Litiere

Outcome of first-line treatment of elderly advanced soft tissue sarcoma (STS) patients: a pooled analysis of eleven EORTC Soft Tissue and Bone Sarcoma Group trials

Proffered Paper session: Breast Cancer, early stage

Abstract: 7324
H. Bonnefoi, W. Jacot, M. Saghatchian, C. Moldovan, L. Venat-Bouvet, K. Zaman, E. Matos, T. Petit, M. Debled, A. Bodmer, P. Vuylsteke, G. Jerusalem, E. Brain, O. Tredan, C.G.M. Messina, L. Slaets, D. Cameron

Neoadjuvant treatment with docetaxel plus lapatinib (L), trastuzumab (T), or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study

Poster Discussion session: Immunotherapy of cancer

Sunday, September 28, 2014, 1:00 PM – 2:00 PM. Room: Valencia

Abstract 1056PD

Eric-Tanis-portraitErik Tanis, Catherine Julie, Jean-Francois Emile, Bernard Nordlinger, Murielle Mauer, Arnaud Roth, Manfred Lutz, Daniela Aust, Theo Ruers

Prognostic impact of immune response in resectable colorectal liver metastases treated with and without perioperative FOLFOX chemotherapy

Poster Discussion session: Gastrointestinal tumours, colorectal

Saturday, September 27, 1:00 PM – 2:00 PM, Room: Granada

Abstract 505PD

H-J--Schmoll-portraitH-J. Schmoll, K. Haustermans, T. Price, B. Nordlinger, R.D. Hofheinz, J-F. Daisne, J. Janssens, B. Brenner, P. Schmidt, H. Reinel, S. Hollerbach, K. Caca, F. Fauth, C.V. Hannig, J. Zalcberg, N. Tebbutt, M.E. Mauer, C. Messina, M.P. Lutz, E. Van Cutsem

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: interim analysis for disease free survival of PETACC-6

ESMO-SEOM Joint Symposium

Monday, September 29, 2:15 PM – 3:45 PM, Room: Granada

Abstract 150IN

Denis Lacombe portraitD.A. Lacombe

The European Perspective of Academic Research: The way to move forwards


Poster Display session: Melanoma and other skin tumours

Monday, September 29, 1:00 PM – 2:00 PM, Room: Valencia

Abstract 1089PD

Stefan-Suciu-portraitS. Suciu, A.M.M. Eggermont, P. Lorigan, J. Kirkwood, S. Markovic, C. Garbe, D. Cameron, S. Kotapati, C. Konto, T.-T. Chen, K. Wheatley, N. Ives, G. De Schaetzen, A. Efendi, M. Buyse

Relapse-free survival (RFS) as a surrogate endpoint for overall survival in adjuvant Interferon trials in patients with resectable cutaneous melanoma: an individual patient data meta-analysis

Poster Display session

Saturday, September 27, 12:45 PM – 1:45 PM, Room: Poster area

Abstract 1244PD

Mary-OBrien-portraitMary 0’Brien, Rabab Gaafar, Baktiar Hasan, Jessica Menis, Tanja Cufer, Sanjay Popat, Penella Woll, Veerle Surmont, Vassilis Georgoulias, Ana Montes, Fiona Blackhall, Ivo Hennig, Gerald Schmid-Bindert, Paul Baas, on behalf of the EORTC Lung Cancer Group

Double blind randomized phase III study of maintenance Pazopanib® versus Placebo in non-Small Cell Lung Cancer patients non progressive after first line chemotherapy (EORTC Lung Cancer Group, 08092): MAPPING

Patient Advocacy Track

Anastassia Negrouk and Denis Lacombe will participate in the 2014 ESMO Patient Advocacy Track.

Anastassia Negrouk portraitAnastassia Negrouk

Saturday, September 27, 10:10 – 10:25, Room: Palma

Pros and Cons of new EU Clinical Trials Regulation

Saturday, September 27, 10:45 – 11:30, Room: Palma

Regulatory process to involve patients in discussions on clinical trial endpoints

Denis Lacombe portraitDenis Lacombe

Saturday, September 27, 11:50 – 12:00, Room: Palma

How can patients be involved in protocol development

Rare Cancers Europe: Special Session: How CT could have been done, and where not, in rare cancers

Jan Bogaerts portraitJan Bogaerts

Monday, September 29, 16:00 – 17:30, Room: Bilbao

Methodological challenges in rare cancers



Back to news list